{"id":816765,"date":"2026-06-01T18:26:01","date_gmt":"2026-06-01T18:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=816765"},"modified":"2026-06-01T18:26:01","modified_gmt":"2026-06-01T18:26:01","slug":"interstitial-cystitis-market-is-expected-to-witness-significant-growth-by-2036-due-to-rising-diagnosis-rates-and-emerging-targeted-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/interstitial-cystitis-market-is-expected-to-witness-significant-growth-by-2036-due-to-rising-diagnosis-rates-and-emerging-targeted-therapies-delveinsight_816765.html","title":{"rendered":"Interstitial Cystitis Market is Expected to Witness Significant Growth by 2036 Due to Rising Diagnosis Rates and Emerging Targeted Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1780292694.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Interstitial Cystitis Market is Expected to Witness Significant Growth by 2036 Due to Rising Diagnosis Rates and Emerging Targeted Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1780292694.jpg\" alt=\"Interstitial Cystitis Market is Expected to Witness Significant Growth by 2036 Due to Rising Diagnosis Rates and Emerging Targeted Therapies | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Interstitial Cystitis market is experiencing steady growth driven by increasing disease awareness, improving diagnosis rates, growing adoption of multimodal treatment strategies, and the development of novel targeted therapies. The emergence of pipeline candidates such as ALENURA (Vaneltix Pharma\/Hyloris Pharma), ONO-1110 (Ono Pharmaceutical), SI-722 (Seikagaku Corporation), Sunobinop\/V117957, and AKP-021 is expected to further strengthen the evolving treatment landscape.<\/div>\n<p style=\"text-align: justify;\">DelveInsight, a leading market research and business consulting company, has released its latest report, &ldquo;Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast &ndash; 2036.&rdquo; The report offers a comprehensive analysis of Interstitial Cystitis, covering epidemiology trends, current treatment practices, emerging therapies, market dynamics, and forecasted market growth across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\">Key Takeaways from the Interstitial Cystitis Market Report<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Interstitial Cystitis market size in the 7MM is projected to grow steadily through 2036.<\/p>\n<\/li>\n<li>\n<p>In 2025, the total diagnosed prevalent cases of Interstitial Cystitis in the 7MM were approximately 3.5 million.<\/p>\n<\/li>\n<li>\n<p>The United States accounted for the largest Interstitial Cystitis market size among the 7MM in 2025, with more than USD 2 billion.<\/p>\n<\/li>\n<li>\n<p>DelveInsight analysis indicates that the US represented more than 55% of total prevalent Interstitial Cystitis cases in the 7MM in 2025.<\/p>\n<\/li>\n<li>\n<p>Within EU4 and the UK, Germany accounted for the highest market size at approximately USD 290 million in 2025.<\/p>\n<\/li>\n<li>\n<p>In Japan, around 75% of Interstitial Cystitis cases were classified as mild, while 22% were moderate and nearly 3% severe in 2025.<\/p>\n<\/li>\n<li>\n<p>Females represented approximately 60% of Interstitial Cystitis cases in the US in 2025, highlighting a clear female predominance.<\/p>\n<\/li>\n<li>\n<p>The Interstitial Cystitis treatment landscape currently includes only two approved therapies, ELMIRON (Johnson &amp; Johnson) and ZYMSO (Kyorin Pharmaceuticals), underscoring the major unmet need for safer and more effective therapies.<\/p>\n<\/li>\n<li>\n<p>Leading companies developing Interstitial Cystitis therapies include Vaneltix Pharma\/Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, and Aska Pharmaceutical.<\/p>\n<\/li>\n<li>\n<p>Promising emerging therapies include ALENURA (lidocaine + heparin), ONO-1110, SI-722, Sunobinop (V117957), and AKP-021.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Keen to know more about the market? Request our sample page at <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/interstitial-cystitis-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">https:\/\/www.delveinsight.com\/sample-request\/interstitial-cystitis-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr<\/a><\/p>\n<p style=\"text-align: justify;\">Key Factors Driving the Interstitial Cystitis Market<\/p>\n<p style=\"text-align: justify;\">Increasing Diagnosis Rates and Disease Awareness:- Growing awareness regarding chronic bladder pain syndromes, along with improved diagnostic approaches such as cystoscopy, urodynamics, and biomarker research, is contributing to earlier and more accurate diagnosis of Interstitial Cystitis.<\/p>\n<p style=\"text-align: justify;\">Rising Adoption of Multimodal Treatment Approaches:- The management of Interstitial Cystitis increasingly relies on individualized treatment strategies involving oral medications, intravesical therapies, pelvic floor therapy, neuromodulation, behavioral modifications, and supportive care approaches.<\/p>\n<p style=\"text-align: justify;\">Growing Demand for Novel and Safer Therapies:- Current therapies are often associated with limited efficacy and safety concerns. For example, long-term retinal toxicity risks associated with pentosan polysulfate sodium are increasing the demand for safer alternatives with improved clinical outcomes.<\/p>\n<p style=\"text-align: justify;\">Advancements in Emerging Pipeline Therapies:- The pipeline for Interstitial Cystitis is expanding with innovative candidates targeting pain relief, inflammation control, bladder lining repair, and neuromodulation pathways. These emerging therapies are expected to reshape future treatment paradigms.<\/p>\n<p style=\"text-align: justify;\">Interstitial Cystitis Competitive Landscape<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Interstitial Cystitis pipeline includes several promising candidates in mid- and late-stage clinical development such as ALENURA (Vaneltix Pharma\/Hyloris Pharma), ONO-1110 (Ono Pharmaceutical), SI-722 (Seikagaku Corporation), Sunobinop\/V117957 (Imbrium Therapeutics), and AKP-021 (Aska Pharmaceutical).<\/p>\n<\/li>\n<li>\n<p>These therapies target diverse mechanisms including glycosaminoglycan stimulation, anti-inflammatory pathways, nociceptin\/orphanin-FQ peptide receptor agonism, endocannabinoid regulation, and mPGES-1 inhibition. The growing focus on mechanism-based therapies reflects the increasing demand for more effective and personalized treatment options for Interstitial Cystitis patients.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Discover more about therapies set to grab major Bipolar Depression market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/interstitial-cystitis-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">Interstitial Cystitis Treatment Landscape<\/a><\/p>\n<p style=\"text-align: justify;\">Recent Developments in the Interstitial Cystitis Market<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>In March 2025, Hyloris announced a positive interim review outcome for the ALENURA clinical trial, with the Independent Data Monitoring Committee recommending continuation of the study. Patient enrollment is expected to be completed by the end of 2025.<\/p>\n<\/li>\n<li>\n<p>In December 2024, Vaneltix Pharma initiated the VNX001-110 clinical trial to evaluate the safety, efficacy, and dosing frequency of ALENURA for Interstitial Cystitis treatment.<\/p>\n<\/li>\n<li>\n<p>ALENURA currently holds patent protection until 2038, providing an extended commercialization opportunity window.<\/p>\n<\/li>\n<li>\n<p>Japan continues to expand awareness and reimbursement access for therapies such as ZYMSO following its launch after NHI price listing approval.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">What is Interstitial Cystitis?<\/p>\n<p style=\"text-align: justify;\">Interstitial Cystitis is a chronic pelvic condition characterized by bladder pain, pressure, urinary urgency, frequency, and persistent inflammation without evidence of infection or other identifiable causes. Patients often experience severe discomfort, frequent urination, nocturia, and reduced quality of life. Diagnosis remains challenging because symptoms frequently overlap with other urinary and pelvic disorders, often resulting in delayed diagnosis.<\/p>\n<p style=\"text-align: justify;\">Interstitial Cystitis Epidemiology Segmentation<\/p>\n<p style=\"text-align: justify;\">The Interstitial Cystitis epidemiology section provides historical and forecasted epidemiological insights across the 7MM from 2022&ndash;2036, segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Prevalent Cases of Interstitial Cystitis<\/p>\n<\/li>\n<li>\n<p>Total Diagnosed Prevalent Cases of Interstitial Cystitis<\/p>\n<\/li>\n<li>\n<p>Age-specific Diagnosed Prevalent Cases of Interstitial Cystitis<\/p>\n<\/li>\n<li>\n<p>Gender-specific Diagnosed Prevalent Cases of Interstitial Cystitis<\/p>\n<\/li>\n<li>\n<p>Severity-specific Diagnosed Prevalent Cases of Interstitial Cystitis<\/p>\n<\/li>\n<li>\n<p>Type-specific Diagnosed Prevalent Cases of Interstitial Cystitis<\/p>\n<\/li>\n<li>\n<p>Total Treated Cases of Interstitial Cystitis<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Scope of the Interstitial Cystitis Market Report<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Therapeutic Assessment: Current marketed and emerging Interstitial Cystitis therapies<\/p>\n<\/li>\n<li>\n<p>Interstitial Cystitis Market Dynamics: Market drivers, barriers, and future opportunities<\/p>\n<\/li>\n<li>\n<p>Key Companies: Johnson &amp; Johnson, Kyorin Pharmaceuticals, Vaneltix Pharma, Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, Aska Pharmaceutical, and others<\/p>\n<\/li>\n<li>\n<p>Key Therapies: ELMIRON, ZYMSO, ALENURA, ONO-1110, SI-722, Sunobinop (V117957), AKP-021, and others<\/p>\n<\/li>\n<li>\n<p>Competitive Intelligence Analysis: SWOT analysis and market entry strategies<\/p>\n<\/li>\n<li>\n<p>Unmet Needs, KOL perspectives, Analyst views, and Market Access &amp; Reimbursement analysis<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">To know more about Bipolar Depression companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/interstitial-cystitis-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">Interstitial Cystitis Market Clinical Trials and Therapeutic Assessment<\/a><\/p>\n<p style=\"text-align: justify;\">Table of Contents<\/p>\n<ol style=\"text-align: justify;\">\n<li>\n<p>Key Insights<\/p>\n<\/li>\n<li>\n<p>Report Introduction<\/p>\n<\/li>\n<li>\n<p>Interstitial Cystitis Market Overview<\/p>\n<\/li>\n<li>\n<p>Methodology of Epidemiology and Market<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Key Events<\/p>\n<\/li>\n<li>\n<p>Disease Background and Overview<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Patient Population<\/p>\n<\/li>\n<li>\n<p>Patient Journey<\/p>\n<\/li>\n<li>\n<p>Marketed Therapies<\/p>\n<\/li>\n<li>\n<p>Emerging Therapies<\/p>\n<\/li>\n<li>\n<p>Interstitial Cystitis &ndash; 7MM Market Analysis<\/p>\n<\/li>\n<li>\n<p>Key Opinion Leaders&#8217; Views<\/p>\n<\/li>\n<li>\n<p>SWOT Analysis<\/p>\n<\/li>\n<li>\n<p>Unmet Needs<\/p>\n<\/li>\n<li>\n<p>Market Access and Reimbursement<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<li>\n<p>About DelveInsight<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">About DelveInsight<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading business consultant and market research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve business performance. DelveInsight offers healthcare market research reports through its subscription-based platform PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kirti Sharma<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=interstitial-cystitis-market-is-expected-to-witness-significant-growth-by-2036-due-to-rising-diagnosis-rates-and-emerging-targeted-therapies-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=interstitial-cystitis-market-is-expected-to-witness-significant-growth-by-2036-due-to-rising-diagnosis-rates-and-emerging-targeted-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Interstitial Cystitis market is experiencing steady growth driven by increasing disease awareness, improving diagnosis rates, growing adoption of multimodal treatment strategies, and the development of novel targeted therapies. The emergence of pipeline candidates such as ALENURA (Vaneltix Pharma\/Hyloris Pharma), &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/interstitial-cystitis-market-is-expected-to-witness-significant-growth-by-2036-due-to-rising-diagnosis-rates-and-emerging-targeted-therapies-delveinsight_816765.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,420,404],"tags":[],"class_list":["post-816765","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/816765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=816765"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/816765\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=816765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=816765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=816765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}